Gold has topped $4,200. Here’s why Yardeni thinks the rally could go even higher.
SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $171 million market cap company with impressive 80% gross margins and "GREAT" financial health according to InvestingPro, announced Wednesday it has entered into a definitive agreement to acquire LoveBiome, a direct sales company specializing in microbiome care and wellness solutions.
The acquisition is expected to close by mid-October, subject to customary closing conditions and regulatory approvals. Financial terms of the transaction were not disclosed. With more cash than debt on its balance sheet and liquid assets exceeding short-term obligations, LifeVantage appears well-positioned to execute this strategic move. InvestingPro analysis reveals 8 additional key insights about the company’s financial strength.
LoveBiome’s flagship P84 product focuses on regulating and restoring gut health. According to the press release, the global gut health supplement market is projected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, with a compound annual growth rate of 8.4%.
"This strategic acquisition represents an acceleration of our mission to offer people around the world a better path to wellness," said Steve Fife, President and CEO of LifeVantage.
The deal structure includes the retention of key LoveBiome personnel, with founder and CEO Kelly Olsen joining LifeVantage to ensure operational continuity.
LifeVantage stated the acquisition will expand its consultant network in key markets including the US, Taiwan, and Europe. The company expects the transaction to be accretive to adjusted earnings per share and adjusted EBITDA in the first year.
The acquisition adds to LifeVantage’s existing product portfolio, which includes the Protandim family of products and the MindBody GLP-1 System.
LifeVantage, headquartered in Lehi, Utah, specializes in nutrigenomics, which studies how nutrition and naturally occurring compounds interact with human genetics. Based on InvestingPro’s Fair Value analysis, the stock currently appears undervalued, with comprehensive research reports available for deeper insights into the company’s growth potential.
In other recent news, LifeVantage Corporation announced significant findings related to its MindBody GLP-1 System. The company reported an average increase of over 200% in GLP-1 hormone levels among participants in combined clinical trials. This marks an improvement from the previously reported 140% increase in GLP-1 levels. The data combines results from a trial conducted in April 2025 with findings from fall 2024. These developments are noteworthy as they highlight advancements in appetite regulation and metabolic health. LifeVantage’s announcement reflects its ongoing commitment to enhancing health and wellness through scientific research. The recent results may draw attention from investors interested in the company’s innovative approaches.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.